Literature DB >> 25535224

Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.

Ketna S Patel1, Philip N Hawkins1, Carol J Whelan1, Julian D Gillmore1.   

Abstract

Cardiac involvement is the main determinant of prognosis in systemic monoclonal immunoglobulin light chain (AL) amyloidosis. Ventricular arrhythmias and sudden cardiac death are not uncommon. The electrical events that precede sudden death, and their potential to be treated effectively, remain undefined. There are no European guidelines for the use of implantable cardioverter defibrillator (ICD) in amyloidosis. ICDs in general are not usually offered to patients with a life expectancy of less than 1 year. We describe a patient who presented with cardiac AL amyloidosis who underwent prophylactic ICD implantation for the prevention of sudden cardiac death during treatment with chemotherapy, in whom life-threatening ventricular arrhythmia was successfully terminated over a 3-year period. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25535224      PMCID: PMC4275756          DOI: 10.1136/bcr-2014-206600

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis.

Authors:  Brandon C Varr; Shirin Zarafshar; Terra Coakley; Michaela Liedtke; Richard A Lafayette; Sally Arai; Stanley L Schrier; Ronald M Witteles
Journal:  Heart Rhythm       Date:  2013-10-10       Impact factor: 6.343

2.  Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death.

Authors:  Grace Lin; Angela Dispenzieri; Peter A Brady
Journal:  Eur Heart J       Date:  2010-01-08       Impact factor: 29.983

3.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Stefan O Schonland; Efstathios Kastritis; Julian D Gillmore; Meletios A Dimopoulos; Thirusha Lane; Andrea Foli; Darren Foard; Paolo Milani; Lisa Rannigan; Ute Hegenbart; Philip N Hawkins; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood       Date:  2013-03-11       Impact factor: 22.113

4.  ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.

Authors:  Andrea M Russo; Raymond F Stainback; Steven R Bailey; Andrew E Epstein; Paul A Heidenreich; Mariell Jessup; Suraj Kapa; Mark S Kremers; Bruce D Lindsay; Lynne Warner Stevenson
Journal:  J Am Coll Cardiol       Date:  2013-03-01       Impact factor: 24.094

5.  Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Authors:  Vaishali Sanchorawala; Daniel G Wright; Michael Rosenzweig; Kathleen T Finn; Salli Fennessey; Jerome B Zeldis; Martha Skinner; David C Seldin
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

6.  Holter monitoring in AL amyloidosis: prognostic implications.

Authors:  G Palladini; G Malamani; F Cò; A Pistorio; F Recusani; E Anesi; P Garini; G Merlini
Journal:  Pacing Clin Electrophysiol       Date:  2001-08       Impact factor: 1.976

7.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Authors:  Shaji Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Colin Colby; Kristina Laumann; Steve R Zeldenrust; Nelson Leung; David Dingli; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

8.  Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.

Authors:  Efstathios Kastritis; Ashutosh D Wechalekar; Meletios A Dimopoulos; Giampaolo Merlini; Philip N Hawkins; Vittorio Perfetti; Julian D Gillmore; Giovanni Palladini
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

9.  Implantable cardioverter defibrillators in patients with cardiac amyloidosis.

Authors:  Grace Lin; Angela Dispenzieri; Robert Kyle; Martha Grogan; Peter A Brady
Journal:  J Cardiovasc Electrophysiol       Date:  2013-03-14

10.  Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

Authors:  Arnt V Kristen; Thomas J Dengler; Ute Hegenbart; Stefan O Schonland; Hartmut Goldschmidt; Falk-Udo Sack; Frederik Voss; Rüdiger Becker; Hugo A Katus; Alexander Bauer
Journal:  Heart Rhythm       Date:  2007-10-09       Impact factor: 6.343

View more
  4 in total

Review 1.  Systemic lupus erythematosus complicated with Castleman disease: a case-based review.

Authors:  Fatma Gül Demirkan; Sümeyra Doğan; Ayşe Kalyoncu Uçar; Hafize Emine Sönmez; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2020-08-14       Impact factor: 2.631

Review 2.  Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).

Authors:  A Yilmaz; J Bauersachs; F Bengel; R Büchel; I Kindermann; K Klingel; F Knebel; B Meder; C Morbach; E Nagel; E Schulze-Bahr; F Aus dem Siepen; N Frey
Journal:  Clin Res Cardiol       Date:  2021-01-18       Impact factor: 5.460

Review 3.  Recent advances in the diagnosis and management of amyloid cardiomyopathy.

Authors:  Petra Nijst; Wh Wilson Tang
Journal:  Fac Rev       Date:  2021-03-24

4.  Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities.

Authors:  Michele Orini; Adam J Graham; Ana Martinez-Naharro; Christopher M Andrews; Antonio de Marvao; Ben Statton; Stuart A Cook; Declan P O'Regan; Philip N Hawkins; Yoram Rudy; Marianna Fontana; Pier D Lambiase
Journal:  J Am Heart Assoc       Date:  2019-09-08       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.